Trial · NCT03653832
Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)
NCT03653832, Phase 3, Completed, University of Edinburgh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial). Trials, record NCT03653832. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03653832
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)
- NCT number
- NCT03653832
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,404 participants, actual
- Lead sponsor
- University of Edinburgh
- Conditions
- Critical Illness
- Interventions
- Dexmedetomidine, Clonidine, Propofol
- First posted
- 2018-08-31
- Last updated
- 2026-10-23
- Other registries' IDs
- eudract:2018-001650-98
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to First Successful Extubation Post-randomisation (Hours). | Ventilation status will be recorded twice daily from the date of randomisation until the date of documented successful extubation, or 180 days, whichever comes first. | The primary outcome is the time from randomisation to the time of successful extubation (in hours post-randomisation)using an internationally agreed definition |
| Secondary | Mortality | The incidence of death as documented in the medical records will be recorded from the date of randomisation until the date of the last follow-up visit at 180 days. | Mortality data collected from medical records, up to 180 days post-randomisation |
| Secondary | Duration of ICU Stay | Time from randomisation until ICU discharge or mortality in ICU | Time from randomisation (days) until ICU discharge or mortality in ICU |
| Secondary | Sedation Quality as Measured by Richmond Agitation and Sedation Scale (RASS) | During ICU stay, up to the occurrence of successful extubation, withdrawal, death, or 28 days post-randomisation, whichever occurred first. | Proportion of patients with highest Richmond Agitation and Sedation Scale (RASS) recorded of -2 or greater. The RASS score measures how sedated or agitated a patient is and ranges from -5 (deeply sedated) to 4 (agitated). |
| Secondary | Sedation Quality as Measured by Sedation Quality Assessment Tool (SQAT) | During ICU stay, up to the occurrence of successful extubation, withdrawal, death, or 7 days post-randomisation, whichever occurred first. | Sedation quality was assessed as measured by the SQAT. We calculated whether there were any days of optimal sedation, agitation, unnecessary deep sedation or pain behaviour during the patient's ICU stay (yes or no). Overall optimum sedation is present when there is no agitation; no unnecessary deep sedation; and no pain behaviour. |
| Secondary | Number of Hours Until First Highest RASS of -2 or Greater | During ICU stay, up to the occurrence of successful extubation, withdrawal, death, or 28 days post-randomisation, whichever occurred first. | Approximate number of hours until first highest Richmond Agitation and Sedation Scale (RASS) recorded of -2 or greater. The RASS score was measured in 12-hour shift periods, and measures how sedated or agitated a patient is and ranges from -5 (deeply sedated) to 4 (agitated). |
| Secondary | Number of Days to First Optimum Sedation as Assessed by the Sedation Quality Assessment Tool (SQAT) | Level of sedation will be assessed daily during the period of ventilation from the date of randomisation until the participant is successfully extubated, or 28 days, whichever comes first. | Number of days to first optimum sedation as assessed by the Sedation Quality Assessment Tool (SQAT) |
| Secondary | Delirium During ICU Stay Within the First 10 Days After Randomisation | During ICU stay, in the first 10 days after randomisation | Did participants have delirium during ICU stay in the 10 days following randomisation? Delirium was assessed by research nurses twice daily during ICU stay using the Confusion-Agitation method for ICU (CAM-ICU). |
| Secondary | Duration of Delirium During ICU Stay | The first 10 days after randomisation during ICU stay | How many days did participants have delirium within the first 10 days after randomisation? |
| Secondary | The Number of Patients With Any Pre-specified Drug-related Adverse Events | Drug-related adverse events as documented in the medical records were recorded daily from the date of randomisation until the date of documented successful extubation, or 28 days, whichever comes first. | The number of patients with drug-related adverse events as documented in the medical records - Bradycardia; cardiac arrhythmias; cardiac arrest |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03653832
GET https://conductscience.org/api/trials/v1/NCT03653832/registered?page=2